Juno Therapeutics, Inc. (JUNO) Reaches $48.75 After 7.00% Down Move; Cisco Systems (CSCO) SI Increased By 14.69%

January 14, 2018 - By wolcottdaily

Cisco Systems Incorporated (NASDAQ:CSCO) had an increase of 14.69% in short interest. CSCO’s SI was 52.14 million shares in January as released by FINRA. Its up 14.69% from 45.46 million shares previously. With 28.34 million avg volume, 2 days are for Cisco Systems Incorporated (NASDAQ:CSCO)’s short sellers to cover CSCO’s short positions. The stock increased 1.92% or $0.77 during the last trading session, reaching $40.87. About 23.77 million shares traded or 19.09% up from the average. Cisco Systems, Inc. (NASDAQ:CSCO) has risen 13.20% since January 14, 2017 and is uptrending. It has underperformed by 3.50% the S&P500.

The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) is a huge mover today! The stock decreased 2.68% or $1.34 during the last trading session, reaching $48.75. About 1.51 million shares traded. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since January 14, 2017 and is downtrending. It has underperformed by 56.55% the S&P500.The move comes after 5 months negative chart setup for the $5.57 billion company. It was reported on Jan, 14 by Barchart.com. We have $45.34 PT which if reached, will make NASDAQ:JUNO worth $389.62M less.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies. The company has market cap of $5.57 billion. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

Analysts await Juno Therapeutics, Inc. (NASDAQ:JUNO) to report earnings on March, 7. They expect $-1.02 EPS, down 54.55% or $0.36 from last year’s $-0.66 per share. After $-1.12 actual EPS reported by Juno Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.93% EPS growth.

Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.11, from 1.33 in 2017Q2. It improved, as 26 investors sold Juno Therapeutics, Inc. shares while 46 reduced holdings. 51 funds opened positions while 53 raised stakes. 66.13 million shares or 23.59% more from 53.50 million shares in 2017Q2 were reported. Rockefeller Services Inc reported 2,633 shares or 0% of all its holdings. Bailard Inc reported 20,000 shares. 956,524 are held by D E Shaw Company Inc. The Unknown-based Mckinley Llc Delaware has invested 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Citigroup, New York-based fund reported 38,930 shares. State Of Wisconsin Inv Board reported 12,955 shares stake. Fred Alger Mgmt holds 22,000 shares or 0% of its portfolio. Savings Bank Of Montreal Can has invested 0% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Tekla Mngmt Limited Liability Corporation invested 0.09% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Deutsche Bankshares Ag holds 0.01% or 258,516 shares in its portfolio. Evercore Wealth Ltd Liability owns 32,062 shares or 0.06% of their US portfolio. Moreover, Pier Cap Ltd Llc has 0.96% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO). Barclays Pcl stated it has 0.01% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Prelude Lc reported 0.1% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Lumina Fund Mgmt Limited Liability owns 0.06% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 13,000 shares.

Among 18 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 10 have Buy rating, 1 Sell and 7 Hold. Therefore 56% are positive. Juno Therapeutics Inc had 46 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Buy” rating by Wedbush on Thursday, November 2. As per Thursday, August 31, the company rating was downgraded by Standpoint Research. As per Thursday, June 8, the company rating was downgraded by BTIG Research. Standpoint Research upgraded the stock to “Buy” rating in Tuesday, December 15 report. The rating was initiated by Raymond James on Thursday, June 2 with “Outperform”. The stock has “Mkt Perform” rating by Raymond James on Tuesday, December 6. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, August 7. Citigroup initiated the shares of JUNO in report on Thursday, February 25 with “Buy” rating. The company was initiated on Wednesday, July 22 by Northland Capital. The rating was initiated by Needham on Friday, January 5 with “Buy”.

Since August 23, 2017, it had 0 buys, and 7 selling transactions for $23.51 million activity. On Thursday, December 14 the insider MCGEARY RODERICK C sold $578,740. On Thursday, December 14 the insider BARTZ CAROL sold $7.59M. Robbins Charles sold $3.89M worth of stock. $821,900 worth of Cisco Systems, Inc. (NASDAQ:CSCO) was sold by BHATT PRAT on Monday, September 11. Another trade for 23,110 shares valued at $740,883 was made by Walker Karen on Monday, September 11. CHANDLER MARK D also sold $2.11M worth of Cisco Systems, Inc. (NASDAQ:CSCO) on Monday, September 18. The insider CHAMBERS JOHN T sold 250,000 shares worth $7.79 million.

Among 37 analysts covering Cisco Systems Inc. (NASDAQ:CSCO), 24 have Buy rating, 0 Sell and 13 Hold. Therefore 65% are positive. Cisco Systems Inc. had 135 analyst reports since August 4, 2015 according to SRatingsIntel. Drexel Hamilton initiated Cisco Systems, Inc. (NASDAQ:CSCO) on Friday, October 9 with “Buy” rating. Pacific Crest maintained Cisco Systems, Inc. (NASDAQ:CSCO) on Wednesday, January 13 with “Overweight” rating. The rating was maintained by Morgan Stanley on Thursday, August 18 with “Equal-Weight”. As per Thursday, August 17, the company rating was maintained by BMO Capital Markets. Argus Research maintained the stock with “Buy” rating in Friday, August 19 report. Deutsche Bank maintained it with “Buy” rating and $4000 target in Tuesday, June 13 report. The firm earned “Buy” rating on Wednesday, June 21 by Credit Suisse. The firm has “Buy” rating given on Thursday, November 16 by Citigroup. The firm earned “Buy” rating on Thursday, August 18 by Deutsche Bank. The company was maintained on Friday, July 21 by Credit Suisse.

Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol based networking and other products related to the communications and information technology industry worldwide. The company has market cap of $202.05 billion. The firm offers switching products, including fixed-configuration and modular switches, and storage products that provide connectivity to end users, workstations, IP phones, wireless access points, and servers; and next-generation network routing products that interconnect public and private wireline and mobile networks for mobile, data, voice, and video applications. It has a 21.29 P/E ratio. It also provides collaboration products comprising unified communications products, conferencing products, collaboration endpoints, and business messaging products; data center products, such as blade and rack servers, series, fabric interconnects, and management software solutions; wireless products consisting of wireless access points, WLAN controllers, cloud and appliances based services, and integrated software services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: